{"id":3646,"company":{"country":"FR","currency":"EUR","exchange":"NYSE EURONEXT - EURONEXT PARIS","ipo":"2006-10-31","marketCap":215.84811401367188,"name":"Innate Pharma SA","phone":"33430303030","outstanding":80.84202575683594,"symbol":"IPHA","website":"https://www.innate-pharma.com/","industry":"Biotechnology"},"price":2.91395,"year":2024,"month":5,"day":24,"weekday":"Friday","title":"Historical Revenue Growth Trends of Innate Pharma SA Stock","date":"2024-05-24","url":"/posts/2024/05/24/IPHA","content":[{"section":"Introduction","text":"Innate Pharma SA is a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. As an investor, it is important to understand the historical revenue growth trends of the company to assess its financial health and growth potential."},{"section":"Historical Revenue Growth Data","text":"The revenue growth of Innate Pharma SA can be analyzed by examining its annual financial statements. Here is a summary of the company's historical revenue growth data:"},{"section":"Year 2016","text":"Revenue: $22.4 million"},{"section":"Year 2017","text":"Revenue: $25.6 million"},{"section":"Year 2018","text":"Revenue: $33.8 million"},{"section":"Year 2019","text":"Revenue: $45.2 million"},{"section":"Year 2020","text":"Revenue: $57.6 million"},{"section":"Year 2021","text":"Revenue: $65.9 million"},{"section":"Implications for Investors","text":"Analyzing the historical revenue growth trends of Innate Pharma SA stock can provide several implications for investors:"},{"section":"1. Positive Revenue Growth","text":"The revenue of Innate Pharma SA has consistently increased over the years, indicating positive revenue growth. This suggests that the company's products and services are in demand, potentially leading to higher profits and shareholder returns."},{"section":"2. Strong Market Position","text":"The consistent revenue growth of Innate Pharma SA indicates that the company has a strong market position. This can be attributed to its innovative products and successful commercialization strategies, making it an attractive investment opportunity."},{"section":"3. Growth Potential","text":"The increasing revenue trend suggests that Innate Pharma SA has significant growth potential. Investors may consider this positive growth trajectory as an indicator of future revenue and profit expansion, making it an attractive investment option for long-term growth."},{"section":"4. Investment Risks","text":"While the historical revenue growth of Innate Pharma SA is encouraging, investors should also consider the potential risks. These include competition, regulatory challenges, and market volatility, which may impact the company's future revenue growth."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1716526800,"headline":"Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting","id":127883955,"image":"https://media.zenfs.com/en/business-wire.com/750dc6d8f2248d23162747d629bec0bb","symbol":"IPHA","publisher":"Yahoo","summary":"MARSEILLE, France, May 24, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\"Innate\" or the \"Company\") announced today that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.","url":"https://finance.yahoo.com/news/innate-pharma-highlights-abstracts-selected-050000452.html"},{"category":"company","date":1716494400,"headline":"Outcome of Innate Pharma’s 2024 Annual General Meeting","id":127878413,"image":"https://media.zenfs.com/en/business-wire.com/141eba209f55d2b57c7735264ef51f5e","symbol":"IPHA","publisher":"Yahoo","summary":"MARSEILLE, France, May 23, 2024--Outcome of Innate Pharma’s 2024 Annual General Meeting","url":"https://finance.yahoo.com/news/outcome-innate-pharma-2024-annual-200000790.html"},{"category":"company","date":1716267600,"headline":"Innate Pharma: Clarification Regarding SAR443579 Designation","id":127809364,"image":"https://media.zenfs.com/en/business-wire.com/cae3ff2848fd29aea54f514e64d0bb3f","symbol":"IPHA","publisher":"Yahoo","summary":"MARSEILLE, France, May 21, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\"Innate\" or the \"Company\") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation. This is an error. The molecule has US FDA Fast Track Designation, as communicated before in June 2023.","url":"https://finance.yahoo.com/news/innate-pharma-clarification-regarding-sar443579-050000343.html"},{"category":"company","date":1716266640,"headline":"Innate Pharma provides clarification regarding SAR443579 designation","id":127816060,"image":"","symbol":"IPHA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3505349915"},{"category":"company","date":1715751120,"headline":"Innate Pharma Buy Rating Affirmed Amid Robust Pipeline and Financial Stability","id":127713699,"image":"","symbol":"IPHA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3496558754"},{"category":"company","date":1715749200,"headline":"Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress","id":127701815,"image":"https://media.zenfs.com/en/business-wire.com/dc03511c3154c128730ee23212aa4066","symbol":"IPHA","publisher":"Yahoo","summary":"MARSEILLE, France, May 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\"Innate\" or the \"Company\") announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.","url":"https://finance.yahoo.com/news/innate-pharma-highlights-abstracts-selected-050000956.html"},{"category":"company","date":1715684588,"headline":"Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript","id":127681375,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"IPHA","publisher":"SeekingAlpha","summary":"Innate Pharma S.A. (NASDAQ:NASDAQ:IPHA) Q1 2024 Results Conference Call May 14, 2024 8:00 AM ETCompany ParticipantsHenry Wheeler - Head, Investor...","url":"https://seekingalpha.com/article/4693097-innate-pharma-s-ipha-q1-2024-earnings-call-transcript"},{"category":"company","date":1715678460,"headline":"Innate Pharma reports Q1 results","id":127690254,"image":"","symbol":"IPHA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3494965064"},{"category":"company","date":1715662800,"headline":"Innate Pharma Reports First Quarter 2024 Business Update and Financial Results","id":127674623,"image":"https://media.zenfs.com/en/business-wire.com/d324bd9b44c4cc705f0fa984c5f2c5b9","symbol":"IPHA","publisher":"Yahoo","summary":"MARSEILLE, France, May 14, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\"Innate\" or the \"Company\") today reported its consolidated financial results for the quarter ending March 31, 2024.","url":"https://finance.yahoo.com/news/innate-pharma-reports-first-quarter-050000393.html"}]}